Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2018 / Cilt: 28 - Sayı: 4

Up-Regulation of the miR-92a and miR-181a in Patients with Acute Myeloid Leukemia and their Inhibition with Locked Nucleic acid (LNA)-antimiRNA; Introducing c-Kit as a New Target Gene

Sayfa
238–247
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Regarding the anti-proliferative effect of LNA-anti-miR-92a and LNA-anti-miR-181a, regulation of miR-92a and miR-181a expression might be a useful approach in line with conventional chemotherapy to limit blast cell survival and reduce leukemic cell proliferation.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Dysregulated expression of various microRNAs (miRNAs) has been widely observed in hematopoietic malignancies like acute myeloid leukemia (AML).
📊
Temel Bulgular & Veri:In this study, we evaluated the expression of the miR-92a and miR-181a in newly diagnosed AML patients compared to healthy controls.
💡
Sonuç & Katkı:Regarding the anti-proliferative effect of LNA-anti-miR-92a and LNA-anti-miR-181a, regulation of miR-92a and miR-181a expression might be a useful approach in line with conventional chemotherapy to limit blast cell survival and reduce leukemic cell proliferation.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Dysregulated expression of various microRNAs (miRNAs) has been widely observed in hematopoietic malignancies like acute myeloid leukemia (AML). In this study, we evaluated the expression of the miR-92a and miR-181a in newly diagnosed AML patients compared to healthy controls. Also, we investigated for the first time the effect of blocking of the miR-92a and miR-181a on the expression of cKit, CEBPA and WT1 genes in HL-60 cell line. For evaluation of the relative gene expression, SYBR Green Real-Time PCR method was performed. The expression of miRNAs was inhibited by transfection of the HL-60 cell line with locked nucleic acid (LNA)-anti-miRNA. The viability of transfected cells was evaluated by MTT assay. Both miR-92a and miR-181a are highly overexpressed in AML patients compared to healthy controls. Also, miR-181a expression was associated with poor prognosis of AML patients. The blockage of the miR-92a and miR-181a remarkably reduces cell viability. In addition, inhibition of miR-92a with LNA-anti-miR-92a significantly decreased c-Kit level. Conversely, miR-181a blockage was associated with upregulated c-Kit expression. Taking together, miR-92a and miR-181a are dysregulated in AML patients and c-Kit gene might be a novel target for these miRNAs. Regarding the anti-proliferative effect of LNA-anti-miR-92a and LNA-anti-miR-181a, regulation of miR-92a and miR-181a expression might be a useful approach in line with conventional chemotherapy to limit blast cell survival and reduce leukemic cell proliferation.

🔖

Bu Makaleye Atıf Yap

SAADI, M. I., ARANDİ, N., YAGHOBI, R., AZARPIRA, N., GERAMIZADEH, B., RAMZİ, M. (2018). Up-Regulation of the miR-92a and miR-181a in Patients with Acute Myeloid Leukemia and their Inhibition with Locked Nucleic acid (LNA)-antimiRNA; Introducing c-Kit as a New Target Gene. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 28 - Sayı: 4, 238–247. https://ajindex.com/articles/322777

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Gabra MM, Salmena L. microRNAs and acute myeloid leukemia chemoresistance: A mechanistic overview. Front Oncol 7: 255, 2017
  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011
  3. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16: 203-222, 2017
  4. Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem 6: 1967-1984, 2014
  5. Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet 208: 225-229, 2015
  6. Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene 34: 3226-3239, 2015
  7. Chen C-Z, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86, 2004
  8. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15: 352-358, 2008
  9. Liao Q, Wang B, Li X, Jiang G. miRNAs in acute myeloid leukemia. Oncotarget 8: 3666-3682, 2017
  10. Li M, Guan X, Sun Y, et al. miR-92a family and their target genes in tumorigenesis and metastasis. Exp Cell Res 323: 1-6, 2014
  11. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20: 1603-1614, 2013
  12. Elhamamsy AR, El Sharkawy MS, Zanaty AF, et al. Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. Int J Mol Cell Med 6: 77-86, 2017
  13. Trino S, Lamorte D, Caivano A, et al. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. Int J Mol Sci 19: 460, 2018
  14. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129: 424-447, 2017
  15. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159, 2012
  16. Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance. Ann Transl Med 3: 332, 2015
  17. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, et al. Down-regulation of miR-92 in human